Advertisement
week in cancer news
  • March 3: The Week in Cancer News

    Exercising only 11 minutes per day can reduce your cancer risk, and new robotic technology helps detect early-stage lung cancer.

    by Thomas Celona

  • February 24: The Week in Cancer News

    Aggressive end-of-life measures are common in people with advanced cancer in nursing homes, and findings suggest immune checkpoint inhibitors could one day be the preferred treatment in localized cancer.

    by Marci A. Landsmann

  • February 17: The Week in Cancer News

    More older women with breast cancer may not need radiation therapy, and supply shortages hinder bladder cancer treatment.

    by Kevin McLaughlin

  • February 10: The Week in Cancer News

    Patients who receive certain forms of chemo face long-term risk for heart failure, and screening levels for certain cancers remain below expectations.

    by Thomas Celona

  • February 3: The Week in Cancer News

    Group says more women should consider removing fallopian tubes to lower ovarian cancer risk, and treatment guidelines can lead to arbitrary age cutoffs.

    by Eric Fitzsimmons

  • January 27: The Week in Cancer News

    Many women underestimate dense breast effect on cancer risk, and FDA approves targeted therapy for colorectal cancer.

    by Kevin McLaughlin

  • January 20: The Week in Cancer News

    Women experience faster decline in physical function after cancer, and treatment quality for lung cancer varies across the US.

    by Marci A. Landsmann

  • January 13: The Week in Cancer News

    Women over 65 diagnosed at later stages of cervical cancer, and Black and Hispanic patients prescribed fewer opioids for end-of-life cancer care.

    by Eric Fitzsimmons

  • January 6: The Week in Cancer News

    Cancer patients have an increased risk of breakthrough COVID-19 infections, and CAR T-cell therapy is safe for lymphoma patients with HIV.

    by Thomas Celona

  • December 16: The Week in Cancer News

    A second KRAS inhibitor is approved for lung cancer, and a BTK inhibitor challenges standard of care for relapsed or refractory CLL.

    by Marci A. Landsmann